Literature DB >> 26201869

Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt.

Yan Ye1, Yan Mei Ge1, Miao Miao Xiao1, Li Mei Guo1, Qun Li1, Ji Qing Hao2, Jie Da2, Wang Lai Hu1, Xu Dong Zhang3, Jiegou Xu4, Lin Jie Zhang5.   

Abstract

BACKGROUND: The Src homology 2-containing inositol 5-phosphatase 2 (SHIP2) is implicated in diabetes, arthrosclerosis, and cancer. However, the role of SHIP2 in human gastric cancer remains unclear.
METHODS: The expression levels of SHIP2 in gastric cancer tissues, a panel of gastric cancer cell lines, and normal gastric epithelial cells were analyzed by immunohistochemistry (IHC), Western blot, and real-time quantitative RT-PCR (qRT-PCR). Gastric cancer cells with either overexpressed SHIP2 or co-overexpressed SHIP2 and Akt were analyzed to determine cell proliferation, colony formation, apoptosis, cell migration, and invasion assays. Normal gastric epithelial cells with knockdown SHIP2 or co-knockdown SHIP2 and Akt were subjected by anchorage-independent growth assays. The effect of SHIP2 on tumor growth in vivo was detected by xenograft tumorigenesis assays.
RESULTS: SHIP2 was commonly downregulated in gastric cancer compared with normal gastric mucosa, and overexpression of SHIP2 inhibited cell proliferation, induced apoptosis, suppressed cell motility and invasion in gastric cancer cells in vitro, and retarded the growth of xenograft gastric tumors in vivo, while knockdown of SHIP2 in normal gastric epithelial cells promoted anchorage-independent growth. Moreover, overexpression of SHIP2 inactivated Akt, and upregulated p21, p27, and the pro-apoptotic protein Bim. Restoring Akt activation in gastric cancer cells largely blocked the inhibition of PI3K/Akt signaling by SHIP2 and reversed the inhibitory effect of SHIP2 on tumorigenesis and proliferation.
CONCLUSIONS: This study demonstrates, for the first time, that SHIP2 is frequently downregulated in gastric cancer, and reduced SHIP2 expression promotes tumorigenesis and proliferation of gastric cancer via activation of the PI3K/Akt signaling.

Entities:  

Keywords:  Akt; Gastric cancer; Proliferation; SHIP2; Tumorigenesis

Mesh:

Substances:

Year:  2015        PMID: 26201869     DOI: 10.1007/s00535-015-1101-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  39 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives.

Authors:  A Bittoni; E Maccaroni; M Scartozzi; R Berardi; S Cascinu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2010-04       Impact factor: 3.507

Review 3.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

4.  Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.

Authors:  Christopher J Ong; Andrew Ming-Lum; Matt Nodwell; Ali Ghanipour; Lu Yang; David E Williams; Joseph Kim; Loutfig Demirjian; Pooran Qasimi; Jens Ruschmann; Li-Ping Cao; Kewei Ma; Stephen W Chung; Vincent Duronio; Raymond J Andersen; Gerald Krystal; Alice L-F Mui
Journal:  Blood       Date:  2007-05-14       Impact factor: 22.113

Review 5.  The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases.

Authors:  Katrien Backers; Daniel Blero; Nathalie Paternotte; Jing Zhang; Christophe Erneux
Journal:  Adv Enzyme Regul       Date:  2003

6.  Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice.

Authors:  Michael P Scheid; Michael Huber; Jacqueline E Damen; Michael Hughes; Veronica Kang; Paul Neilsen; Glenn D Prestwich; Gerald Krystal; Vincent Duronio
Journal:  J Biol Chem       Date:  2002-01-07       Impact factor: 5.157

7.  Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits Akt/protein kinase B phosphorylation and leads to apoptotic cell death.

Authors:  Marina V Kisseleva; Li Cao; Philip W Majerus
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

8.  Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover.

Authors:  Nagendra K Prasad; Manish Tandon; Sunil Badve; Paul W Snyder; Harikrishna Nakshatri
Journal:  Carcinogenesis       Date:  2007-09-24       Impact factor: 4.944

9.  The docking properties of SHIP2 influence both JIP1 tyrosine phosphorylation and JNK activity.

Authors:  Jingwei Xie; Sheela Onnockx; Isabelle Vandenbroere; Chantal Degraef; Christophe Erneux; Isabelle Pirson
Journal:  Cell Signal       Date:  2008-03-26       Impact factor: 4.315

10.  The inositol 5-phosphatase SHIP2 is an effector of RhoA and is involved in cell polarity and migration.

Authors:  Katsuhiro Kato; Tsubasa Yazawa; Kentaro Taki; Kazutaka Mori; Shujie Wang; Tomoki Nishioka; Tomonari Hamaguchi; Toshiki Itoh; Tadaomi Takenawa; Chikako Kataoka; Yoshiharu Matsuura; Mutsuki Amano; Toyoaki Murohara; Kozo Kaibuchi
Journal:  Mol Biol Cell       Date:  2012-05-16       Impact factor: 4.138

View more
  17 in total

1.  PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.

Authors:  Wenli Cui; Shutao Zheng; Xinxia Li; Yuqing Ma; Wei Sang; Ming Liu; Wei Zhang; Xiaoyan Zhou
Journal:  Tumour Biol       Date:  2016-07-22

Review 2.  INPPL1 gene mutations in opsismodysplasia.

Authors:  Anaïs Fradet; Jamie Fitzgerald
Journal:  J Hum Genet       Date:  2016-10-06       Impact factor: 3.172

3.  Solution structure of SHIP2 SH2 domain and its interaction with a phosphotyrosine peptide from c-MET.

Authors:  Zi Wang; Yao Nie; Kunxiao Zhang; Henghao Xu; Theresa A Ramelot; Michael A Kennedy; Maili Liu; Jiang Zhu; Yunhuang Yang
Journal:  Arch Biochem Biophys       Date:  2018-08-27       Impact factor: 4.013

4.  The Sam-Sam interaction between Ship2 and the EphA2 receptor: design and analysis of peptide inhibitors.

Authors:  Flavia Anna Mercurio; Concetta Di Natale; Luciano Pirone; Roberta Iannitti; Daniela Marasco; Emilia Maria Pedone; Rosanna Palumbo; Marilisa Leone
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

5.  Decreased Sp1 Expression Mediates Downregulation of SHIP2 in Gastric Cancer Cells.

Authors:  Yan Ye; Xue Yi Qian; Miao Miao Xiao; Yu Ling Shao; Li Mei Guo; Dong Ping Liao; Jie Da; Lin Jie Zhang; Jiegou Xu
Journal:  Int J Mol Sci       Date:  2017-01-22       Impact factor: 5.923

6.  Underexpression of INPPL1 is associated with aggressive clinicopathologic characteristics in papillary thyroid carcinoma.

Authors:  Yi-Li Zhou; Chen Zheng; Yi-Tong Chen; Xue-Min Chen
Journal:  Onco Targets Ther       Date:  2018-11-01       Impact factor: 4.147

7.  Curcumin regulates the miR-21/PTEN/Akt pathway and acts in synergy with PD98059 to induce apoptosis of human gastric cancer MGC-803 cells.

Authors:  Zhanrong Qiang; Lingyu Meng; Caixia Yi; Lianying Yu; Wenxia Chen; Weihong Sha
Journal:  J Int Med Res       Date:  2019-02-06       Impact factor: 1.671

8.  Upregulation of SHIP2 participates in the development of breast cancer via promoting Wnt/β-catenin signaling.

Authors:  Juan Zhou; Manman Di; Hui Han
Journal:  Onco Targets Ther       Date:  2019-08-30       Impact factor: 4.147

9.  IRTKS Promotes Insulin Signaling Transduction through Inhibiting SHIP2 Phosphatase Activity.

Authors:  Chongchao Wu; Xiaofang Cui; Liyu Huang; Xueying Shang; Binghao Wu; Na Wang; Kunyan He; Zeguang Han
Journal:  Int J Mol Sci       Date:  2019-06-11       Impact factor: 5.923

10.  MicroRNA-129-5p Regulates Glycolysis and Cell Proliferation by Targeting the Glucose Transporter SLC2A3 in Gastric Cancer Cells.

Authors:  Di Chen; Hui Wang; Jie Chen; Zhe Li; Shengli Li; Zhixiang Hu; Shenglin Huang; Yingjun Zhao; Xianghuo He
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.